A Phase 2 interventional study of APG777 and Placebo in Atopic Dermatitis, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 9 that started in 2024, is one of 6 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 25th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:
Apogee Therapeutics, Inc. · Sites in United States, Canada, Czechia and 6 more countries
Ages 18+
AbbVie · Sites in United States
Ages 18–75
AbbVie
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 470 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 228 across the 22 interventional studies, 300 across the 11 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Apogee Therapeutics, Inc., one of the names counted as AbbVie. Under that name alone:
Apogee Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
7 of the studies in Dermatitis, Atopic by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT05669794AbbVieAn Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World | 2027-02 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Dermatitis, Atopic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined inclusion/exclusion criteria may apply.
Participants will receive APG777 per protocol defined dosing regimen
Drug: APG777
Participants will receive matching Placebo injections per protocol defined dosing regimen
Drug: Placebo
Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen
Drug: APG777
Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen
Drug: APG777
Participants will receive matching placebo injections per protocol defined dosing regimen
Drug: Placebo
Participants will receive APG777 per protocol defined dosing regimen
Drug: APG777
APG777 subcutaneous injection
Matching placebo subcutaneous injection
Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)
Time frame: Baseline and at Week 16
Part B: Proportion of participants who achieve EASI 75 at Week 16
Time frame: At Week 16
Part A and B: Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 106 Weeks
Part A and B: Change from Baseline in EASI
Time frame: Baseline, through Week 16 and at Week 52
Part A and B: Percent Change from Baseline in EASI
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Proportion of Participants Achieving EASI 50, 75, 90, and 100 Score
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Proportion of Participants Achieving a Validated Investigator Global Assessment (vIGA-AD) Score of 0 (clear) or 1 (almost clear) and a >= 2-Point Reduction
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Change from Baseline in Body Surface Area (BSA) Involvement
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Proportion of Participants Achieving a >= 4 Point Improvement in the Weekly Mean of the Daily Itch Numeric Rating Scale (I-NRS)
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Percent Change from Baseline in the Weekly Mean of the Daily I-NRS
Time frame: Baseline through Week 16 and at Week 52
Part A and B: Serum Concentrations of APG777 Over Time
Time frame: Up to 106 Weeks
Part A and B: Predose Serum Concentrations of APG777 (Ctrough)
Time frame: Up to 106 Weeks
Part A and B: Maximum concentration (Cmax) of APG777
Time frame: Up to 106 Weeks
Part A and B: Time to reach Cmax (tmax)
Time frame: Up to 106 Weeks
Part A and B: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUC0-t) in the Induction Period
Time frame: Baseline to 16 Weeks
Part A and B: AUC Over the Dosing Interval (AUC0-tau) in the Maintenance Period
Time frame: 16 Weeks to 52 Weeks
Plan to share: No
Started Apr 2024 (actual). Primary completion is estimated for Nov 2026, 31 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 31 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zumilokibart